[pcrh]

I can't speak for the other pitch decks, but to anyone with any knowledge of how medical testing works in practice, Theranos was a clear fraud from day 1. This derives from the simple observation that almost all current blood tests eventually measure only a small sample (microlitres) of the blood initially drawn, and the business proposition didn't address the question of why larger samples are normally drawn (a lot of the answer lies in the "engineering" problems inherent in handling complex biological liquids).

Obviously, the Theranos deck wasn't pitched to people with the requisite knowledge...

[manv1]

I know of a company that's using dried blood for testing, which apparently is the same as what Theranos was saying from a layman's point of view.

The level of process you're talking about usually isn't in a deck; it's usually "get sample - mail it in - get results."

Decks are pitched to investors, who most of the time have more money than technical skills in the area in question.

[whatever1]

But they were pitching their own testing hardware that supposedly had solved these engineering problems.

Not sure how just from the deck I could had called them out.

[ska]

After seed round anyway, a red flag was a combination of the technical hand waving and having the wrong sort of board for the product. In earliest decks you can only really look at the team anyway. I'm not sure you could reliably discount them in the first 6 mo, say.